Prospira ENT Expands Leadership Team with Key Industry Experts

San Francisco, CA – March 1st 2025 – Prospira ENT, an emerging biotech company developing a bioabsorbable implant for long-lasting allergy relief, is pleased to announce the addition of Jayson Slotnik to our advisory team. This new appointment brings deep expertise in reimbursement and regulatory strategy, strengthening Prospira’s position as it advances toward human clinical trials.

Joining the team are:

Justin Chickles, CEO, has 25+ years of experience in commercial strategy, innovation, and fundraising, with leadership roles at Johnson & Johnson, Mobile Sense, and Glycyx Therapeutics. He specializes in growth strategies and partnerships in medical devices and therapeutics.

Andrew Goldberg, MD, CMO, is a UCSF Professor and Director of Rhinology with 20+ years of experience in medical device innovation. He has 160+ publications, 4 patents, and expertise in nasal and airway inflammation.

David Conrad, MD, is a board-certified otolaryngologist and Prospira’s chief inventor, contributing to its IP, prototyping, and founding team.

Dan Bernards, PhD, is a UCSF Senior Researcher in drug delivery, with expertise in degradable polymers and co-founder of Oculinea.

Nicole Jiam, MD, is a physician-entrepreneur, co-founder of IIAM Corporation, and advisor on MedTech innovations globally.

“As we continue to advance toward first-in-human clinical studies, having a world-class team with deep experience in biotech innovation, regulatory strategy, and commercialization is critical,” said Justin Chickles, CEO of Prospira ENT. “We are thrilled about our team as we work toward bringing a transformative allergy treatment to market.”

Prospira ENT is committed to reshaping allergy treatment through innovative, long-lasting solutions. For more information about the company and its leadership team, contact prospiraent@gmail.com.